Cantor Fitzgerald reissued their buy rating on shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research note published on Friday. Cantor Fitzgerald currently has a $21.00 price target on the biopharmaceutical company’s stock.
ABEO has been the subject of a number of other reports. FBR & Co restated a buy rating on shares of Abeona Therapeutics in a research report on Wednesday, June 22nd. Rodman & Renshaw restated a buy rating and set a $17.00 price objective on shares of Abeona Therapeutics in a research report on Sunday, August 21st. Maxim Group set a $6.00 price objective on Abeona Therapeutics and gave the stock a buy rating in a research report on Thursday, August 18th. Finally, Zacks Investment Research upgraded Abeona Therapeutics from a sell rating to a hold rating in a research report on Wednesday, July 20th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $14.00.
Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 6.01 on Friday. Abeona Therapeutics has a 12 month low of $2.05 and a 12 month high of $6.80. The firm has a 50-day moving average of $5.00 and a 200 day moving average of $3.33. The firm’s market cap is $201.61 million.
Abeona Therapeutics (NASDAQ:ABEO) last released its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. On average, equities research analysts anticipate that Abeona Therapeutics will post ($0.73) EPS for the current fiscal year.
In other news, Director Todd Wider purchased 5,000 shares of Abeona Therapeutics stock in a transaction dated Tuesday, September 20th. The stock was acquired at an average cost of $5.48 per share, for a total transaction of $27,400.00. Following the acquisition, the director now directly owns 75,000 shares in the company, valued at $411,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 13.00% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in shares of Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares in the last quarter. BlackRock Fund Advisors raised its stake in shares of Abeona Therapeutics by 8.5% in the first quarter. BlackRock Fund Advisors now owns 302,262 shares of the biopharmaceutical company’s stock valued at $774,000 after buying an additional 23,734 shares in the last quarter. Sabby Management LLC raised its stake in shares of Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares in the last quarter. Finally, Royce & Associates LP raised its stake in shares of Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares in the last quarter. Institutional investors and hedge funds own 19.95% of the company’s stock.
About Abeona Therapeutics
Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.
Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.